Sam Straw

@NIHRresearch Clinical Lecturer @universityleeds | Cardiology ST6 🫀 @LeedsHospitals | Cyclist 🚲 @vive_velo

[Sam Straw @DrSamStraw]

Some researchers win the @NobelPrize

Some researchers publish in @NEJM

Some researchers change practice forever

Our research led @bmj_latest to print the words sh**, f**k, w***ker, and cr**

So who's the real winner? 😂

Our 🎄Christmas BMJ 🎄article: https://t.co/1L36LiMZSZ

[JACC Journals @JACCJournals]

In pts w/ #HFrEF, having concurrent T2DM further worsens their prognosis. Read about a potential mechanism in #JACCBTS where Dr. @OllyBrown, et al show endothelial cells from subQ fat of HF+DM patients drive a pro-inflammatory adipocyte phenotype. https://t.co/emtFxOxtYA #T2D

[ESC Council on Stroke Chairperson @ESCStrokeChair]

We're thrilled to host @drjohnm for the 1st episode of #ESC Cardio Talk - CoS Podcast🚀

Listen to the great debate on #LAAO: when, how, and in whom? on all your favourite apps

🖇️https://t.co/bBAiOjrxAM

@escardio @JacopoImberti @LiverpoolCCS @Fra_Vitali90

[Ahmed Bennis MD 🫀 @drbennisahmed]

Body Mass Index, Clinical Outcomes, and Mortality in Heart Failure: A Mendelian Randomization Study

Among patients with HF, higher BMI was associated with increased all-cause mortality and cardiovascular death or HF hospitalization, supporting the potential role of weight-management strategies across the ejection fraction spectrum.
@JACCJournals @ACCinTouch @gcfmd @SJGreene_md @DrMarthaGulati @hvanspall
https://t.co/sonVmoAOCF

[Andrew Ladwiniec @ALadwiniec]

We have a vacancy at Glenfield for a consultant in structural intervention. This is a fantastic opportunity to join a well established and high volume structural intervention service.

https://t.co/LeVe8qKkek

[Andrew Flett @drflett]

Sites in BRITISH trial. (We have Adelaide too!) 579 patients so far.
HFA meeting I see other contemporary ICD trials... (See replies) Together, We will redefine the landscape. @TheBHF @SouthamptonCTU @ncurzen

[HFAPresident @HFA_President]

“More than 6,000 people joined us here at #HeartFailure26, fantastic science, fantastic discussions, & an incredible #HF community.”

Prof. @WilfriedMullens reflects on the remarkable energy & momentum of this year’s congress; and reminds us that the journey continues 🇬🇧
See you in London for #HeartFailure27! 👏

#HFA_ESC @escardio @MarcoMetra @jozinetm

[HFAPresident @HFA_President]

Day 3 in Barcelona & the energy at #HeartFailure26 is still through the roof!🫀

Listen to President-elect @GianluSava on the many exciting things happening throughout the congress, also the inspiring atmosphere at #HFACareerCafe connecting the next generation of the #HeartFailure community

#HFAMotions #HFA_ESC @escardio @jozinetm #HFAyoung

[Novi Yanti Sari @slumberbell]

🫀Is there a “non-obese” #HFpEF phenotype?

At #HeartFailure26, Prof. @MarcoMetra discussed how obesity/adiposity is a major driver of HFpEF through inflammation, altered adipokines, but not all HFpEF patients are obese

Potential drivers of non-obese HFpEF:
- Hypertension & LVH
- Coronary microvascular dysfunction
- AF & atrial disease
- Pulmonary vascular disease

@escardio @WilfriedMullens @HFA_President

[HFAPresident @HFA_President]

🫀Full house at the #HeartFailure26 Highlights Session!

The #HFA_ESC is wrapping up an incredible congress with rapid-fire updates across the entire spectrum of heart failure, from basic science, imaging, to HFrEF, HFpEF, devices, acute HF & nursing.

#HeartFailure @es@escardio @MarcoMetra @WilfriedMullens @GianluSava

[HFAPresident @HFA_President]

The SUBCUT-HF II Journal Club is LIVE at the #HFAStudio by #ESCTV! 🎥🫀

Join us at #HeartFailure26 for an insightful discussion on subcutaneous furosemide and its potential role in acute #HeartFailure care

#HFA_ESC #HFAyoung @jozinetm @escardio @markcpetrie20 @DukeHFDoc @GTersalvi

[Dr. Hadi Skouri @HSkouri]

Cardiac Glycosides Revisited or they are still here ?
DECISION trial DECISION withdrawal and DIGIT-HF
For All HFrEF or for a HFrEF phenotype ?
Meta analysis results are reassuring !
#HeartFailure26 @AmrAbdin10 @slumberbell @SotiriaLiori @DrSamStraw @jozinetm @corneliacrm

[Sotiria Liori @SotiriaLiori]

Young investigator award basic science at #HeartFailure26 and let me tell you sth: The force is strong with these young ones 🤗✨

@jozinetm @corneliacrm @slumberbell @Arakisheva @AmrAbdin10 @HSkouri @DrSamStraw @WilfriedMullens @GianluSava @HFA_President #HFA_ESC

[Novi Yanti Sari @slumberbell]

What a fantastic atmosphere at the HFA Championship Finals at #HeartFailure26
🏆🫀

Congratulations to Team India🇮🇳 for taking the win, with impressive performances as well from Team Norway🇳🇴 as runner-up & Team Holland🇳🇱 👏👏👏

Listen to each representation of the team, together with chair @mitja_lainscak, celebrating teamwork, friendship, & excellence in #HeartFailure knowledge across the global cardiology community

@pmyhre @escardio
#HFAYoung #HFA_ESC #HFAmotions

[European Society of Cardiology Journals @ESC_Journals]

Viral respiratory tract infections in heart failure: the FINEARTS-HF trial 👇
https://t.co/F9oX2mr0DN

#HeartFailure26 #HFA_ESC @HFA_President @FaiezZANNAD @ragnhildhelseth @lamcardio

[Novi Yanti Sari @slumberbell]

🧬Can targeting microRNA pathways modify post-MI remodeling & prevent progression to #HF?

��HF-REVERT: microRNA-132 inhibitor CDR132L in patients with reduced LVEF after MI. Presented at #HeartFailure26 by Prof. @JBauersachsMD

📍Phase 2 randomized, double-blind, placebo-controlled trial
📍Primary endpoint (% change in LVESVI at 6 months) improved across groups, but differences were not statistically significant between groups
📍Secondary endpoints including LVEF, NT-proBNP, GLS, & KCCQ also showed no significant differences
📍Exploratory subgroup analyses suggested potential benefit in patients with more advanced adverse remodeling at baseline
📍CDR132L was generally well tolerated with no hepatic, renal, hematologic, or cardiotoxicity signals

@escardio @HFA_President @scottdsolomon @rudolf_deboer

[Novi Yanti Sari @slumberbell]

@jozinetm & @KlausKWitte spotted in action at the #HFAstudio for #ESCTV 🎥🎬

Make sure to catch the upcoming episodes featuring expert discussions, clinical insights, & the latest updates from #HeartFailure26 🫀

#HFA_ESC #HeartFailure #HFAyoung @HFA_President @escardio

[Novi Yanti Sari @slumberbell]

What I learned the hard way in #HeartFailure care?

Not every setback means failure.
Sometimes the missed opportunity, rejected papers, difficult case, or moment of being overlooked becomes the experience that sharpens your clinical judgment, resilience, & purpose.

In our career, growth often comes quietly:
🫀listening more carefully
🫀staying curious
🫀learning from patients & your mentors
🫀building consistency
🫀showing up again

Early-career setbacks can become the foundation for future impact, if we keep going🥹❤️

Fantastic panels & sharing @KlausKWitte @ARakisheva @noshreza @corneliacrm & Floran Sahiti #HFAyoung

@escardio @HFA_President @jozinetm @MarcoMetra

[Novi Yanti Sari @slumberbell]

🫀 What happens when long-term low-dose #digoxin is suddenly withdrawn?
Blinded withdrawal analysis from the #DECISION trial presented at #HeartFailure26 by Prof. Peter van der Meer:

📍Digoxin withdrawal was associated with a ~7x increase in worsening HF events over just 6 weeks
📍14 worsening HF events occurred after digoxin withdrawal vs only 2 events in placebo withdrawal
📍Withdrawal was accompanied by: ⬆️HR,⬇️ SBP, ⬆️NT-proBNP, ⬇️eGFR
📍⚠️caution when stopping long-term low-dose digoxin in pts with HF & LVEF <=50%

@escardio @HFA_President @jozinetm

[Novi Yanti Sari @slumberbell]

🫀Is there still a role for low-dose #digoxin in modern HF therapy?
Primary results from the #DECISION trial presented by Prof. Dirk van Veldhuisen at #HeartFailure26:

📍Low-dose digoxin did not significantly ⬇️ the primary composite endpoint of CV mortality + total worsening HF events
📍However, there was a non-significant 24% relative ⬇️ in worsening HF events
📍In the as-treated analysis, digoxin was associated with a 34% relative risk ⬇️ in the primary outcome
📍Low-dose digoxin was generally safe & well tolerated, including in women & patients with #AFib
📍High study-drug discontinuation rates ➡️ reduced statistical power

@escardio @HFA_President @jozinetm #LBCT

[Novi Yanti Sari @slumberbell]

Congratulations to the finalists of the Nursing & Allied Professions Investigator Award at #HeartFailure26 👏🫀

Outstanding presentations highlighting the breadth of contemporary HF research:
📍William Baker : phenotypic clustering in heart transplantation
📍Ziyi Zhong : sarcopenia, metabolic profiling & incident HF in the UK Biobank
📍Tessa Duk : sex differences in prognostic factors among patients with CKD hospitalized with HF

Wonderful discussions & inspiring science from all finalists! #HFA_ESC #HFAmotions @jozinetm